ESMO Immuno-Oncology 2022 | Developing a FOXC1-based immunohistochemistry assay for basal-like breast cancer

Partha Ray, MD, Onconostic Technologies, Evanston, IL, provides an overview of utilizing FOXC1, a biomarker associated with plasticity in cancer cells, in a immunohistochemistry assay for basal-like breast cancer (BLBC). FOXC1 has been associated with BLBC and is additionally highly expressed in many aggressive tumors that metastasize earlier and to the brain and lung. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.